个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Recent research and development of inhibitors targeting sentrin-specific protease 1 for the treatment of cancers

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Wei Junxia[1,5] ; Wang Huijing[2] ; Zheng Qinwen[1,4] ; Zhang Jifa[1,5] ; Chen Zhichao[1] ; Wang Jiaxing[3] ; Ouyang Liang[1,5] ; Wang Yuxi[1,4,5,*1] ;
机构： [1]Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China [2]Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, 610041, China [3]Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, 38163, Tennessee, United States [4]Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China [5]Tianfu Jincheng Laboratory, Chengdu, 610041, Sichuan, China
出处：
DOI： 10.1016/j.ejmech.2022.114650
ISSN：

关键词： SENP1 SUMO Small-molecular inhibitors Structure-activity relationship Cancer treatment

摘要：
Small ubiquitin-like modifier (SUMO)/sentrin-specific protease 1 (SENP1), is a cysteine protease that promotes SUMO maturation and deSUMOylation of target proteins and regulates transcription factors or co-regulatory factors to mediate gene transcription. Many studies have shown that SENP1 is the driving factor for a multitude of cancers including prostate cancer, liver cancer, and breast cancer. Inhibition of SENP1 activity has been proved to inhibit the survival, proliferation, invasion, and migration of cancer cells, and increase their chemical and radiation sensitivity. Therefore, SENP1 is a promising anti-tumor target. At present, peptide inhibitors of SENP1 have entered clinical trials. Recently, many small molecule compounds and natural products were synthesized and identified as SENP1 inhibitors, and showed good tumor inhibitory activity in vitro and in vivo. This review summarizes the structure, physiological function, and role of SENP1 in tumorigenesis and development, focusing on the design and discovery of small molecule inhibitors of SENP1 from the perspective of medicinal chemistry, providing ideas for the development and research of small molecule inhibitors of SENP1 in the future.Copyright © 2022 Elsevier Masson SAS. All rights reserved.

基金：
This review was supported by Sichuan Science and Technology Program (2019YFS0003), National Natural Science Foundation of China (82073318, 81922064, 81903502), and National Major Scientific and Technological Special Project for Significant New Drugs Development (2018ZX09201018-021), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2020-JKCS-014), and the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD20001).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 药物化学
最新[2023]版：
大类 | 2 区 医学
小类 | 1 区 药物化学
第一作者：
第一作者机构： [1]Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China [5]Tianfu Jincheng Laboratory, Chengdu, 610041, Sichuan, China
共同第一作者：
通讯作者：
通讯机构： [1]Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China [4]Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China [5]Tianfu Jincheng Laboratory, Chengdu, 610041, Sichuan, China [*1]Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
推荐引用方式(GB/T 7714)：
Wei Junxia,Wang Huijing,Zheng Qinwen,et al.Recent research and development of inhibitors targeting sentrin-specific protease 1 for the treatment of cancers[J].European journal of medicinal chemistry.2022,241:114650.doi:10.1016/j.ejmech.2022.114650.
APA：
Wei Junxia,Wang Huijing,Zheng Qinwen,Zhang Jifa,Chen Zhichao...&Wang Yuxi.(2022).Recent research and development of inhibitors targeting sentrin-specific protease 1 for the treatment of cancers.European journal of medicinal chemistry,241,
MLA：
Wei Junxia,et al."Recent research and development of inhibitors targeting sentrin-specific protease 1 for the treatment of cancers".European journal of medicinal chemistry 241.(2022):114650

相关文献

[1]Structure-Activity Relationship of Novel Pyrimidine Derivatives with Potent Inhibitory Activities against Mycobacterium tuberculosis [2]Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer. [3]Synthesis, optimization and antitumor activity evaluation of sulfonyl benzoyl hydrazide derivatives as novel human LSD1 inhibitors [4]Dual-target inhibitors based on COX-2: a review from medicinal chemistry perspectives [5]RIPK2 inhibitors for disease therapy: Current status and perspectives [6]Recent discovery and development of AXL inhibitors as antitumor agents [7]Development of novel focal adhesion kinase (FAK) inhibitors for targeting cancer: Structural insights and therapeutic potential [8]Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy [9]Structural and functional characteristics of pectins from three cultivars of apple (Malus pumila Mill.) pomaces [10]Cyclen-based lipidic oligomers as potential gene delivery vehicles.

资源点击量：46425 今日访问量：0 总访问量：3323 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号